دورية أكاديمية
Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison From the FRANCE-TAVI Registry
| العنوان: | Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison From the FRANCE-TAVI Registry |
|---|---|
| المؤلفون: | Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric |
| المساهمون: | Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand |
| المصدر: | ISSN: 0009-7322. |
| بيانات النشر: | HAL CCSD American Heart Association |
| سنة النشر: | 2020 |
| المجموعة: | LillOA (HAL Lille Open Archive, Université de Lille) |
| مصطلحات موضوعية: | aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system |
| الوصف: | International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007 |
| DOI: | 10.1161/CIRCULATIONAHA.119.043785 |
| الإتاحة: | https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test https://univ-rennes.hal.science/hal-02472206Test https://univ-rennes.hal.science/hal-02472206/documentTest https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.23A07593 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/CIRCULATIONAHA.119.043785 |
|---|